This article examines a role for gabapentin in reducing alcohol consumption in a specific subpopulation of alcohol use disorder patients: those with high alcohol intake and high levels of withdrawal symptoms.
The anxiolytic phenibut has gained popularity due to its availability online, despite being banned by the FDA. This case report illustrates the misuse and abuse potential and life-threatening consequences.
This study aimed to quantitatively assess the type, duration, and amount of alcohol consumed and the association with biochemical markers and liver function tests. Read on and find out what they learned.
Wernicke-Korsakoff syndrome is a life-threatening and underdiagnosed neuropsychiatric condition caused by thiamine deficiency. This case series provides insight into the importance of recognition and adequate treatment.
Here, read about 2 cases of disulfiram-ethanol reaction leading to watershed area infarct in both patients and probable ischemia in one. These cases emphasize the need for rigorous patient education before prescribing disulfiram.
People with psychotic disorders are more likely to have alcohol use disorder than the general population, but how does that comorbidity affect the course of their psychosis? This analysis of data from the CATIE study investigates that question.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”